Advertisement

Epidemiology of Dementia: The Burden on Society, the Challenges for Research

  • Frank J. Wolters
  • MA Ikram
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1750)

Abstract

Dementia is among the leading causes of death and disability. Due to the ageing population, its prevalence is expected to nearly triple worldwide by 2050, urging the development of preventive and curative interventions. Various modifiable risk factors have been identified in community-based cohort studies, but insight into the underlying pathophysiological mechanisms is lacking. Clinical trials have thus far failed in the development of disease-modifying therapy in patients with dementia, thereby triggering a shift of focus toward the presymptomatic phase of disease. The extensive preclinical disease course of Alzheimer’s disease warrants reliable, easily obtainable biomarkers to aid in timely application of preventive strategies, selecting participants for neuroprotective trials, and disease monitoring in trials and clinical practice. Biomarker and drug discovery may yield the fruits from technology-driven developments in the field of genomics, epigenetics, metabolomics, and brain imaging. In that context, bridging the gap between translational and population research may well prove a giant leap toward development of successful preventive and curative interventions against dementia.

Key words

Dementia Alzheimer’s disease Epidemiology Population-based Omics Prevention Genetics Imaging 

References

  1. 1.
    Alzheimer’s Disease International (2016) World Alzheimer Report 2016 alz.co.uk
  2. 2.
    Kelley AS, McGarry K, Gorges R, Skinner JS (2015) The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med 163:729–736Google Scholar
  3. 3.
    Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532Google Scholar
  4. 4.
    Alzheimer’s Society UK (2013) Low expectations. Attitudes on choice, care and community for people with dementia in care homes, 2013 edn. alzheimers.org.uk
  5. 5.
    Etters L, Goodall D, Harrison BE (2008) Caregiver burden among dementia patient caregivers: a review of the literature. J Am Acad Nurse Pract 20:423–428Google Scholar
  6. 6.
    Luengo-Fernandez R, Leal J, Gray A (2015) UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open 5:e006648Google Scholar
  7. 7.
    Zhang Y, Kivipelto M, Solomon A, Wimo A (2011) Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis 26:735–744Google Scholar
  8. 8.
    Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216Google Scholar
  9. 9.
    Jitapunkul S, Chansirikanjana S, Thamarpirat J (2009) Undiagnosed dementia and value of serial cognitive impairment screening in developing countries: a population-based study. Geriatr Gerontol Int 9:47–53Google Scholar
  10. 10.
    Savva GM, Arthur A (2015) Who has undiagnosed dementia? A cross-sectional analysis of participants of the Aging, Demographics and Memory Study. Age Ageing 44:642–647Google Scholar
  11. 11.
    Anonymous (2015) A global assessment of dementia, now and in the future. Lancet 386:931Google Scholar
  12. 12.
    Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37Google Scholar
  13. 13.
    Biotechnology Innovation Organization, Biomedtracker, Amplion Clinical Development Success Rates 2006–2015, 2016 edn. bio.org
  14. 14.
    de Bruijn RFAG, Bos MJ, Portegies MLP, Hofman A, Franco OH, Koudstaal PJ, Ikram MA (2015) The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med 13:132Google Scholar
  15. 15.
    Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13:788–794Google Scholar
  16. 16.
    Matthews FE, Stephan BCM, Robinson L, Jagger C, Barnes LE, Arthur A, Brayne C, Collaboration CFaASC (2016) A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun 7:11398Google Scholar
  17. 17.
    Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S (2016) Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 374:523–532Google Scholar
  18. 18.
    Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB (2012) Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78:1456–1463Google Scholar
  19. 19.
    Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B (2015) Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14:926–944Google Scholar
  20. 20.
    Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk. elderly people (FINGER): a randomised controlled trial. Lancet 385(9984):2255–2263Google Scholar
  21. 21.
    Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi M-N, Dantoine T, Dartigues J-F, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere J-P, Weiner M, Carrié I, Ousset P-J, Vellas B, Group MS (2017) Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16:377–389Google Scholar
  22. 22.
    Moll van Charante EP, Richard E, Eurelings LS, van Dalen J-W, Ligthart SA, van Bussel EF, Hoevenaar-Blom MP, Vermeulen M, van Gool WA (2016) Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet 388:797–805Google Scholar
  23. 23.
    Knopman DS (2008) Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol 21:197–201Google Scholar
  24. 24.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847Google Scholar
  25. 25.
    Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JNE, Warlow CP, Mehta Z (2005) A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366:29–36Google Scholar
  26. 26.
    Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, Forgie M, Kovacs G, Ward J, Kovacs MJ (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135:98–107Google Scholar
  27. 27.
    Tang EYH, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BCM (2015) Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One 10:e0136181Google Scholar
  28. 28.
    Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 15:673–684Google Scholar
  29. 29.
    Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R (2014) Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (6):CD008782Google Scholar
  30. 30.
    Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (7):CD010386Google Scholar
  31. 31.
    Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NHH, Robin Hsiung G-Y, Hyman B, Iqbal K, Kaeser SA, Käser SA, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Group AAQPW (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 9:251–261Google Scholar
  32. 32.
    Sackett DL, Haynes RB (2002) The architecture of diagnostic research. BMJ 324:539–541Google Scholar
  33. 33.
    Drachman DA (2014) The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement 10:372–380Google Scholar
  34. 34.
    Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC (2014) Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17:661–663Google Scholar
  35. 35.
    Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP (1975) The Framingham Offspring Study. Design and preliminary data. Prev Med 4:518–525Google Scholar
  36. 36.
    Hofman A, Brusselle GGO, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CCW, Nijsten TEC, Peeters RP, Stricker BHC, Tiemeier HW, Uitterlinden AG, Vernooij MW (2015) The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 30:661–708Google Scholar
  37. 37.
    Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP, Investigators OLT (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489–1499Google Scholar
  38. 38.
    Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Investigators O-LSoL-TEaLCO (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500–1509Google Scholar
  39. 39.
    Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen W-M, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161–169Google Scholar
  40. 40.
    Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856–860Google Scholar
  41. 41.
    Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B (2013) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12:35–50Google Scholar
  42. 42.
    Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai L-H, Kellis M (2015) Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature 518:365–369Google Scholar
  43. 43.
    Ikram MA (2015) Molecular pathological epidemiology: the role of epidemiology in the omics-era. Eur J Epidemiol 30:1077–1078Google Scholar
  44. 44.
    Watts G (2007) UK Biobank gets 10% response rate as it starts recruiting volunteers. BMJ 334:659Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of EpidemiologyErasmus Medical CentreRotterdamThe Netherlands
  2. 2.Departments of Epidemiology, Radiology, NeurologyErasmus University Medical Center RotterdamRotterdamThe Netherlands

Personalised recommendations